Key
Publications:
Key
Publications
Surface
phospholipids in gastric injury and protection when a selective cyclooxygenase-2
inhibitor(coxib) is used in combination with aspirin. Submitted to the British
Journal of Pharmacology.
NSAID
injury to the gastrointestinal tract: evidence that NSAIDs interract with
phospholipids to weaken the hydrophobic surface barrier and induce the formation
of unstable pores in membranes. Journal of Pharmacy and Pharmacology. 58:
1-8, 2006.
Phosphatidylcholine-associated
no-steroidal antiflammatory drugs (NSAIDS) inhibit DNA systhesis and the growth
of colon cancer cells in vitro. Cancer Chemother Pharmacol. 57: 295-300, 2005.
Aspirin
in the XXI century: its major clinical impact, novel mechanisms of action,
and new safer formulations. Gastroenterology. 2004 Jul;127(1):341-3.
The
effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and
prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology.
2004 Jul;127(1):94-104.
Phosphatidylcholine
association increases the anti-inflammatory and analgesic activity of ibuprofen
in acute and chronic rodent models of joint inflammation: relationship to
alterations in bioavailability and cyclooxygenase (COX) - inhibitory potency.
J. Pharmacol. Exp. Therap. 298: 279-287, 2001.
Where
is the evidence that cyclooxygenase inhibition is the primary cause of non-steroidal
anti-inflammatory drug (NSAID) - induced gastrointestinal toxicity? Topical
injury revisited. Biochem. Pharmacol. 61: 631-637, 2001.
Effect
of bisphosphonates on surface hydrophobicity and phsophatidylcholine concentration
of the rodent gastric mucosa. Dig. Dis. Sci. 45: 1792-1801, 2000.
Lichtenberger,
L.M. Evidence that phospholipid association reduces the gastric mucosal toxicity
of aspirin in human subjects. Am. J.Gastroenterol.94: 1818-1822, 1999.
Interaction
of indomethacin and naproxen with gastric surface-active phospholipids: a
possible mechanism for the gastric toxicity of non-steroidal anti-inflammatory
drugs (NSAIDs). Biochem. Pharmacol. 57: 247-254, 1999.
Phospholipids
- associated aspirin accelerates healing of gastric ulcers in rats. Dig. Dis.
Sciences 43: 786-790, 1998.
Effect
of omeprazole on the bioavailability of unmodified and phospholipid-complexed
aspirin in rats. Aliment Pharmacol Ther. 1997 Oct;11(5):899-906.
Nonsteroidal anti-inflammatory
drug and phospholipid prodrugs: combination therapy with antisecretory agents
in rats. Gastroenterology. 1996 Oct;111(4):990-5.
witterionic
phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent
model systems. J. Pharmacol. Exp. Therap. 277: 1221-1227, 1996.
NSAIDs
associate with zwitterionic phospholipids: Insight into the mechanism and
reversal of NSAID-induced GI injury. Nature Med. 1:154-158, 1995.
Gastric
protective activity of mixtures of polar and neutral lipids in rats. Gastroenterology
99:311-326, 1990.
Does
aspirin damage the canine gastric mucosa by reducing its surface hydrophobicity?
Am. J. Physiol.: Gastro. and Liver Physiol.15:G421-430, 1987.
Role
of surface-active phospholipids in gastric cytoprotection. Science 219:1327-1329,
1983
Gastric
Mucosal Barrier: The hydrophobic lining to the lumen of the stomach. Am. J.
Physiol.: Gastro. and Liver Physiol. 7:G561-568, 1983.
.
